FDA Recalls Veklury Injection Vials for Presence of Glass Particles
Gilead Sciences recalls 105,000 vials of Veklury (remdesivir) for injection nationwide because glass particles are present in the medication.
The agency’s classification
FDA (Drugs): Class I
Class I is a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The FDA classified this as a Class I drug recall, which by definition scores no lower than 4. No deaths or reported illnesses are mentioned in the source text.
Plain-English summary
Gilead Sciences, Inc. is recalling Veklury (remdesivir) for injection, 100 mg per vial. The recall affects 105,000 vials with Lot number 47035CFA and expiration date November 2025, distributed nationwide in the United States.
The recall is due to the presence of glass particles in the vials. The FDA has classified this as a Class I recall, the most serious type of recall classification.
Healthcare providers and facilities that have received affected vials should cease distribution and use immediately.
The recalled product
- Product
- VEKLURY (REMDESIVIR)
- Brand
- VEKLURY
- Manufacturer
- Gilead Sciences, Inc.
- Category
- Drug — Intravenous Injection
- Hazard
- Affected units
- 105,000
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot: 47035CFA
- Exp. 11/2025
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · VEKLURY
- SevereVeklury (Remdesivir) Drug Vials Recalled for Glass Particulate Matter
FDA (Drugs) · 2022-01-05
Same manufacturer · Gilead Sciences, Inc.
See all →- ModerateGilead Recalls Emtriva Oral Solution Due to Defective Leaking Containers
FDA (Drugs) · 2014-11-05
- LowGilead Recalls Truvada Tablets Due to Silicone Rubber Particulates
FDA (Drugs) · 2014-10-15
- LowGilead Recalls Atripla Tablets Due to Foreign Silicone Particulates
FDA (Drugs) · 2014-03-05
- HighGilead Recalls AmBisome Injection Due to Potential Sterility Assurance Issues
FDA (Drugs) · 2013-07-31
- SevereGilead Recalls Vistide Injection Due to Particulate Matter
FDA (Drugs) · 2013-05-22
Same hazard · glass particles
See all →- SevereFresenius Kabi Recalls Tyenne Injection Due to Glass Particles
FDA (Drugs) · 2026-09-02
- HighDexamethasone and moxifloxacin injection recalled over glass-like particulate matter
FDA (Drugs) · 2026-01-14
- HighTri-Moxi intraocular injection recalled over glass-like particulate matter
FDA (Drugs) · 2026-01-14
- HighIntraocular injection syringes recalled over glass-like particulate matter
FDA (Drugs) · 2026-01-14
- ModerateTestosterone Pellet 100 mg recalled due to glass particle contamination
FDA (Drugs) · 2025-05-14
Similar recalls
- SevereVeklury (Remdesivir) Drug Vials Recalled for Glass Particulate Matter
FDA (Drugs) · 2022-01-05
- SevereGilead Recalls Vistide Injection Due to Particulate Matter
FDA (Drugs) · 2013-05-22
- CriticalSun Pharmaceutical Recalls Vecuronium Bromide Due to Glass Particulates
FDA (Drugs) · 2019-01-16
- SevereDrug recall: Bleomycin injection vials recalled due to glass contamination
FDA (Drugs) · 2024-01-31
- CriticalPfizer Recalls Vancomycin Hydrochloride Vials Due to Glass Particulate Matter
FDA (Drugs) · 2017-12-27
- ModerateFDA recalls Verapamil Hydrochloride injectable due to cross contamination
FDA (Drugs) · 2024-07-17